Colleagues have been finding their way to work on their newly purchased JobRad bicycles for several months now. However, the associated CO2 savings are not enough for us. Transo-Pharm has set itself the goal of further minimizing its CO2 footprint.
 
For this reason, the first fully electric vehicles can now be found in our fleet - more will follow. Consequently, we have installed eight wall boxes on our company premises with which colleagues can easily charge their vehicles.
 
Transo-Pharm has also invested in its own photovoltaic system to cover its own operational electricity consumption.
With these steps we are gradually working to become greener - for our environment.

Epinephrine Base and Epinephrine Bitartrate have been in our portfolio even before we acquired the IP from the originator Boehringer Ingelheim. Over the last couple of years our customers have expressed their need for Norepinephrine Bitartrate and we listened.
 
We have proudly partnered up with hameln rds s.r.o. a Slovakian based API producer who has developed a robust Norepinephrine production process. The CEP has been issued by EDQM July 26, 2024. In this partnership, Transo-Pharm will focus on all commercial aspects and hameln rds will concentrate on production and quality.

We're saddened to hear about the passing of our long-time team member Artan "Tani" Bekteshi. Tani has been taking care of our warehousing and logistics for 20 years. He did this with extreme devotion and an outstanding perfection. 

He will be immensely missed.

​Our hearts and thoughts are with his family. 

We wish everyone during this holiday season - after a challenging year - a peaceful and relaxing time with their families and friends.

The Transo-Pharm team wishes you all a happy, healthy and safe New Year.

Let’s put all our hope and confidence in 2024!